{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:15:50Z","timestamp":1780614950086,"version":"3.54.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015015","name":"Government of South Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["W15QKN-20-9-1003"],"award-info":[{"award-number":["W15QKN-20-9-1003"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["W15QKN-21-9-1003"],"award-info":[{"award-number":["W15QKN-21-9-1003"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["UM1 AI 148372"],"award-info":[{"award-number":["UM1 AI 148372"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["UM1 AI 148450"],"award-info":[{"award-number":["UM1 AI 148450"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["UM1 AI 148574"],"award-info":[{"award-number":["UM1 AI 148574"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["UM1 AI 148684"],"award-info":[{"award-number":["UM1 AI 148684"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.xcrm.2022.100882","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T01:38:58Z","timestamp":1671068338000},"page":"100882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection"],"prefix":"10.1016","volume":"4","author":[{"given":"Anastasia A.","family":"Aksyuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deidre","family":"Wilkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Stanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Sproule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Maaske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satya","family":"Sanikommui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena E.","family":"Sobieszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann R.","family":"Falsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6988-8576","authenticated-orcid":false,"given":"Elizabeth J.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2022.100882_bib1","series-title":"Chapter 94 - The mucosal immune response to respiratory viruses","author":"Lambrecht","year":"2015"},{"key":"10.1016\/j.xcrm.2022.100882_bib2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2022.100882_bib3","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2022.100882_bib4","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2022.100882_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2022.100882_bib6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"W\u00f6lfel","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2022.100882_bib7","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of COVID-19","volume":"386","author":"Levin","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2022.100882_bib8","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2022.100882_bib9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cell.2020.05.042","article-title":"SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract","volume":"182","author":"Hou","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2022.100882_bib10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41591-020-0868-6","article-title":"SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes","volume":"26","author":"Sungnak","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2022.100882_bib11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41385-020-00359-2","article-title":"The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection","volume":"14","author":"Gallo","year":"2021","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.xcrm.2022.100882_bib12","doi-asserted-by":"crossref","first-page":"611337","DOI":"10.3389\/fimmu.2020.611337","article-title":"Mucosal immunity in COVID-19: a neglected but critical aspect of SARS-CoV-2 infection","volume":"11","author":"Russell","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2022.100882_bib13","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1016\/j.cell.2021.07.023","article-title":"Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19","volume":"184","author":"Ziegler","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2022.100882_bib14","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1038\/s41467-021-25949-x","article-title":"SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms","volume":"12","author":"Fr\u00f6berg","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2022.100882_bib15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/22221751.2021.1872352","article-title":"Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission","volume":"10","author":"Kim","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.xcrm.2022.100882_bib16","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1080\/21645515.2015.1114195","article-title":"Induction of mucosal immunity through systemic immunization: phantom or reality?","volume":"12","author":"Su","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.xcrm.2022.100882_bib17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41590-018-0260-6","article-title":"The establishment of resident memory B cells in the lung requires local antigen encounter","volume":"20","author":"Allie","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2022.100882_bib18","author":"United Kingdom Department of Health and Social Care"},{"key":"10.1016\/j.xcrm.2022.100882_bib19","doi-asserted-by":"crossref","first-page":"eabj7211","DOI":"10.1126\/scitranslmed.abj7211","article-title":"AZD1222\/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific TH1 response with a diverse TCR repertoire","volume":"13","author":"Swanson","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2022.100882_bib20","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","article-title":"T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2022.100882_bib21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2022.100882_bib22","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2022.100882_bib23","series-title":"NCT04516746: phase III double-blind, placebo-controlled study of AZD1222 for the prevention of COVID-19 in adults","year":"2020"},{"key":"10.1016\/j.xcrm.2022.100882_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1385","article-title":"Validation and performance of a multiplex serology assay to quantify antibody responses following SARS-CoV-2 infection or vaccination","volume":"11","author":"Wilkins","year":"2022","journal-title":"Clin. Transl. Immunology"},{"key":"10.1016\/j.xcrm.2022.100882_bib25","doi-asserted-by":"crossref","first-page":"eabd2223","DOI":"10.1126\/scitranslmed.abd2223","article-title":"IgA dominates the early neutralizing antibody response to SARS-CoV-2","volume":"13","author":"Sterlin","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2022.100882_bib26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/thx.41.5.337","article-title":"Immunoglobulins in the lung","volume":"41","author":"Burnett","year":"1986","journal-title":"Thorax"},{"key":"10.1016\/j.xcrm.2022.100882_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd9149","article-title":"Airborne transmission of respiratory viruses","volume":"373","author":"Wang","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2022.100882_bib28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nri1439","article-title":"NALT- versus Peyer's-patch-mediated mucosal immunity","volume":"4","author":"Kiyono","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2022.100882_bib29","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1038\/nm1213","article-title":"Mucosal immunity and vaccines","volume":"11","author":"Holmgren","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2022.100882_bib30","doi-asserted-by":"crossref","first-page":"103788","DOI":"10.1016\/j.ebiom.2021.103788","article-title":"Mucosal immune response in BNT162b2 COVID-19 vaccine recipients","volume":"75","author":"Azzi","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.xcrm.2022.100882_bib31","doi-asserted-by":"crossref","first-page":"744887","DOI":"10.3389\/fimmu.2021.744887","article-title":"The mucosal and serological immune responses to the novel coronavirus (SARS-CoV-2) vaccines","volume":"12","author":"Chan","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2022.100882_bib32","doi-asserted-by":"crossref","first-page":"24448","DOI":"10.1038\/s41598-021-03931-3","article-title":"Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccination","volume":"11","author":"Mades","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2022.100882_bib33","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41385-022-00511-0","article-title":"Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection","volume":"15","author":"Sheikh-Mohamed","year":"2022","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.xcrm.2022.100882_bib34","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1038\/s41467-022-32389-8","article-title":"SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals","volume":"13","author":"Sano","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2022.100882_bib35","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1128\/jcm.25.3.559-562.1987","article-title":"Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum","volume":"25","author":"Wagner","year":"1987","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.xcrm.2022.100882_bib36","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.tim.2021.03.016","article-title":"Durability of immunity to SARS-CoV-2 and other respiratory viruses","volume":"29","author":"Siggins","year":"2021","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.xcrm.2022.100882_bib37","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1016\/S2666-5247(21)00219-6","article-title":"The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study","volume":"2","author":"Townsend","year":"2021","journal-title":"Lancet. Microbe"},{"key":"10.1016\/j.xcrm.2022.100882_bib38","doi-asserted-by":"crossref","first-page":"13207","DOI":"10.1038\/s41598-022-17514-3","article-title":"Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study","volume":"12","author":"Yegorov","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2022.100882_bib39","doi-asserted-by":"crossref","first-page":"eabj0299","DOI":"10.1126\/science.abj0299","article-title":"Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"373","author":"Corbett","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2022.100882_bib40","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaci.2020.10.040","article-title":"Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19","volume":"147","author":"Cervia","year":"2021","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.xcrm.2022.100882_bib41","doi-asserted-by":"crossref","first-page":"eabe5511","DOI":"10.1126\/sciimmunol.abe5511","article-title":"Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients","volume":"5","author":"Isho","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.xcrm.2022.100882_bib42","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/s41590-021-01028-7","article-title":"Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection","volume":"22","author":"Smith","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2022.100882_bib43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4049\/jimmunol.1601775","article-title":"Inducing mucosal IgA: a challenge for vaccine adjuvants and delivery systems","volume":"199","author":"Boyaka","year":"2017","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2022.100882_bib44","doi-asserted-by":"crossref","first-page":"836492","DOI":"10.3389\/fimmu.2022.836492","article-title":"SARS-CoV-2 spike protein expression in\u00a0vitro and hematologic effects in mice vaccinated with AZD1222 (ChAdOx1 nCoV-19)","volume":"13","author":"Stebbings","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2022.100882_bib45","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/cid\/ciab465","article-title":"Circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine antigen detected in the plasma of mRNA-1273 vaccine recipients","volume":"74","author":"Ogata","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100882_bib46","doi-asserted-by":"crossref","first-page":"e20220780","DOI":"10.1084\/jem.20220780","article-title":"SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and CD4+ T\u00a0cells of broad specificity","volume":"219","author":"Lim","year":"2022","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2022.100882_bib47","doi-asserted-by":"crossref","first-page":"eadd4853","DOI":"10.1126\/sciimmunol.add4853","article-title":"Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination","volume":"7","author":"Tang","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.xcrm.2022.100882_bib48","doi-asserted-by":"crossref","first-page":"e155655","DOI":"10.1172\/jci.insight.155655","article-title":"Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans","volume":"7","author":"Jeyanathan","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2022.100882_bib49","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(14)70845-X","article-title":"Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial","volume":"14","author":"Satti","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100882_bib50","doi-asserted-by":"crossref","first-page":"e1002790","DOI":"10.1371\/journal.pmed.1002790","article-title":"Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial","volume":"16","author":"Manjaly Thomas","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.xcrm.2022.100882_bib51","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/imm.13526","article-title":"Vaccines, adjuvants and key factors for mucosal immune response","volume":"167","author":"Correa","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.xcrm.2022.100882_bib52","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.chom.2022.01.003","article-title":"Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections","volume":"30","author":"Terreri","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.xcrm.2022.100882_bib53","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.2021.22898","article-title":"Antibody response and variant cross-neutralization after SARS-CoV-2 breakthrough infection","volume":"327","author":"Bates","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2022.100882_bib54","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.3390\/cells10102541","article-title":"Highly specific memory B cells generation after the 2nd dose of BNT162b2 vaccine compensate for the decline of serum antibodies and absence of mucosal IgA","volume":"10","author":"Piano Mortari","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.xcrm.2022.100882_bib55","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/S0264-410X(03)00078-1","article-title":"Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia","volume":"21","author":"Ito","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2022.100882_bib56","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.4049\/jimmunol.173.3.1978","article-title":"Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract","volume":"173","author":"Renegar","year":"2004","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2022.100882_bib57","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/CVI.00590-15","article-title":"Mucosal IgG levels correlate better with respiratory syncytial virus load and inflammation than plasma IgG levels","volume":"23","author":"Vissers","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.xcrm.2022.100882_bib58","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial","volume":"397","author":"Emary","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2022.100882_bib59","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1093\/cid\/ciab986","article-title":"Infection with the SARS-CoV-2 Delta variant is associated with higher recovery of infectious virus compared to the Alpha variant in both unvaccinated and vaccinated individuals","volume":"75","author":"Luo","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100882_bib60","doi-asserted-by":"crossref","first-page":"105151","DOI":"10.1016\/j.jcv.2022.105151","article-title":"SARS-CoV-2 infections in mRNA vaccinated individuals are biased for viruses encoding spike E484K and associated with reduced infectious virus loads that correlate with respiratory antiviral IgG levels","volume":"150-151","author":"Mostafa","year":"2022","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.xcrm.2022.100882_bib61","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/eji.202249823","article-title":"ChAdOx1-S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination","volume":"52","author":"Cokari\u0107 Brdov\u010dak","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.xcrm.2022.100882_bib62","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41573-022-00495-3","article-title":"Antibodies to combat viral infections: development strategies and progress","volume":"21","author":"Pantaleo","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2022.100882_bib63","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-020-01179-4","article-title":"Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses","volume":"27","author":"Barrett","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2022.100882_bib64","doi-asserted-by":"crossref","first-page":"e160565","DOI":"10.1172\/JCI160565","article-title":"Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6\u00a0months","volume":"132","author":"Sobieszczyk","year":"2022","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2022.100882_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2017.06.008","article-title":"Comparison of mucosal lining fluid sampling methods and influenza-specific IgA detection assays for use in human studies of influenza immunity","volume":"449","author":"de Silva","year":"2017","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.xcrm.2022.100882_bib66","doi-asserted-by":"crossref","first-page":"109400","DOI":"10.1016\/j.celrep.2021.109400","article-title":"A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters","volume":"36","author":"Bricker","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2022.100882_bib67","doi-asserted-by":"crossref","first-page":"109452","DOI":"10.1016\/j.celrep.2021.109452","article-title":"An intranasal vaccine durably protects against SARS-CoV-2 variants in mice","volume":"36","author":"Hassan","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2022.100882_bib68","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","article-title":"A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2","volume":"183","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2022.100882_bib69","doi-asserted-by":"crossref","first-page":"eabh0755","DOI":"10.1126\/scitranslmed.abh0755","article-title":"Intranasal ChAdOx1 nCoV-19\/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models","volume":"13","author":"van Doremalen","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2022.100882_bib70","doi-asserted-by":"crossref","first-page":"104298","DOI":"10.1016\/j.ebiom.2022.104298","article-title":"Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: an open-label partially-randomised ascending dose phase I trial","volume":"85","author":"Madhavan","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.xcrm.2022.100882_bib71","doi-asserted-by":"crossref","first-page":"14835","DOI":"10.1021\/acs.analchem.2c01320","article-title":"Multiplex hybrid antigen-capture LC-MRM quantification in sera and nasal lining fluid of AZD7442, a SARS-CoV-2-targeting antibody combination","volume":"94","author":"Mu","year":"2022","journal-title":"Anal. Chem."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379122004463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379122004463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:54:28Z","timestamp":1762988068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379122004463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2666379122004463"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2022.100882","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2022.100882","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"100882"}}